ClostraBio

ClostraBio is a biotech focusing on a root cause of gut barrier dysfunction to improve gut health (food sensitivity, IBS, and IBD). Their lead product is a next-gen, IP-protected, butyrate-producing probiotic, CLB101™. Butyrate is known to improve gut barrier function, reduce inflammation, and modulate the microbiome, thus is expected to play an important role in food sensitivity and allergy. ClostraBio undertook a series of preclinical toxicology studies to demonstrate safety of the novel CLB101™ probiotic, culminating in GRAS self-affirmation to enable marketing in the US. Their first CLB101™ product launched in September, via the Healthcare Practitioner Channel, and thus the company is excited for a near-term opportunity to help people with gut health issues.
The company is derisked, and they are in the phase of commercialization and product growth.